CAS 129536-23-8

hymenistatin I

Description:

Hymenistatin I is a natural product classified as a peptide, specifically a cyclic peptide, derived from the marine sponge Hymeniacidon sp. It exhibits a unique structure characterized by a cyclic arrangement of amino acids, which contributes to its biological activity. This compound has garnered interest in the field of medicinal chemistry due to its potential antitumor properties, as it has shown activity against various cancer cell lines in preliminary studies. Hymenistatin I operates through mechanisms that may involve the inhibition of specific cellular pathways, although the exact mode of action is still under investigation. Additionally, its structural features may influence its solubility and stability, which are critical factors for therapeutic applications. As a compound of natural origin, hymenistatin I represents a promising lead for drug development, particularly in oncology, and highlights the importance of marine biodiversity in the search for novel bioactive substances. Further research is necessary to fully elucidate its pharmacological potential and to explore its synthesis and modification for enhanced efficacy.

Formula: C₄₇H₇₂N₈O₉

Hymenistatin I

CAS: 129536-23-8

Hymenistatin I (HS-I) exerts an immunosuppressive effect in the humoral and cellular immune responses comparable with that of cyclosporin A (CsA). Comparison of the influence of HS-I and CsA on cytokine production suggests that the mechanisms of the interaction with the immunological system are substantially different for the two compounds tested.

Formula: C₄₇H₇₂N₈O₉

Purity: 99.3%

Color and Shape: White Powder

Molecular weight: 893.14

Ref: 01-4026849

Hymenistatin I Cyclo(-Pro-Pro-Tyr-Val-Pro-Leu-Ile-Ile)

CAS: 129536-23-8

Hymenistatin I is a cyclic peptide that is synthesized from the natural amino acid L-proline. It has been shown to inhibit tumor growth and is used in the treatment of bladder cancer. The synthesis of Hymenistatin I begins with the protection of proline as an N-tert-butyloxycarbonyl derivative, followed by a sequence of coupling reactions. This synthetic process involves the use of a linker, such as tetrazole or succinimidyl ester, for example. The final product can then be purified by HPLC analysis. Hymenistatin I inhibits calcineurin inhibitor, which are immunosuppressive agents that are used to treat lymphocytic leukemia and other autoimmune diseases.

Formula: C₄₇H₇₂N₈O₉

Purity: Min. 95%

Molecular weight: 893.12 g/mol

Ref: 3D-FH109026